In the future, patients in critical care hospital settings in the USA can be treated with the fast-working beta blocker Rapibloc (active ingredient: Landiolol). For this purpose, AOP Orphan has concluded a licensing agreement with Eagle Pharmaceuticals Inc. based in New Jersey. Approval by the United States Food and Drug Administration (FDA) is planned for the beginning of 2022.
Landiolol has been on the market in Japan for close to 20 years and was brought to Europe by AOP Orphan in 2017. The drug from the group of β1 blockers is used for the acute treatment of supraventricular tachycardia (overly quick heartbeat) or an irregular heartbeat (arrhythmia) during or after an operation. AOP Orphan Pharmaceuticals GmbH specialises in rare and complex diseases. The company has its headquarters in Vienna and operates other facilities in Europe, the Middle East and North Africa.
Continue reading and find out more about the life sciences location of Austria!